The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to www.galdermausa.com/Our-Commitment/Resident-Education.aspx. Also, there is a website dedicated to the Pre-Board for registration-www.preboard.com. The program will be available from April 15, 2016 to November 15, 2016.
1. These benign hair follicle tumors are part of an inherited syndrome associated with chromophobe and oncocytic types of renal tumors. Additional important pathology is likely to be found in the:
a) Lung
b) Liver
c) Pancreas
d) Thyroid
e) Uterus
2. This patient developed a flushing reaction during cancer chemotherapy. The most likely cause is:
a) Cyclophosphamide
b) Vincristine
c) Vinblastine
d) Etoposide
e) Doxorubicin
3. In this surgical procedure, which of the following was used safely in the patient, who is allergic to lidocaine?
a) Mepivacaine
b) Prilocaine
c) Bupivacaine
d) Etidocaine
e) Procaine
4. This patient has a blistering disorder characterized by circulating immunoglobulin G autoantibodies directed against laminin 5 in the epithelial basement membrane. The most common disease associated is:
a) Biliary cirrhosis
b) Primary pulmonary hypertension
c) Retinitis pigmentosa
d) Visceral adenocarcinoma
e) Mucosal squamous cell carcinoma